Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions

Conclusion: [18F]FAPI-74 PET showed higher uptake and detection rates in primary and metastatic lesions than did [18F]FDG PET. [18F]FAPI-74 PET is a promising novel diagnostic modality for various tumors, especially for precise staging before treatment, including characterization of tumor lesions before surgery. Moreover, 18F-labeled FAPI ligand might serve a higher demand in clinical care in the future.

Source: Journal of Nuclear Medicine - August 1, 2023 Category: Nuclear Medicine Authors: Watabe, T., Naka, S., Tatsumi, M., Kamiya, T., Kimura, T., Shintani, Y., Abe, K., Miyake, T., Shimazu, K., Kobayashi, S., Kurokawa, Y., Eguchi, H., Doki, Y., Inohara, H., Kato, H., Mori, Y., Cardinale, J., Giesel, F. L. Tags: Clinical Investigations Source Type: research